<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="case-report"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cureus</journal-id><journal-id journal-id-type="iso-abbrev">Cureus</journal-id><journal-id journal-id-type="issn">2168-8184</journal-id><journal-title-group><journal-title>Cureus</journal-title></journal-title-group><issn pub-type="epub">2168-8184</issn><publisher><publisher-name>Cureus</publisher-name><publisher-loc>Palo Alto (CA)</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11785457</article-id><article-id pub-id-type="doi">10.7759/cureus.76723</article-id><article-categories><subj-group subj-group-type="heading"><subject>Internal Medicine</subject></subj-group><subj-group><subject>Rheumatology</subject></subj-group><subj-group><subject>Dermatology</subject></subj-group></article-categories><title-group><article-title>Adult-Onset Still's Disease With Normal Ferritin Levels and Severe Sulfasalazine-Induced Probable Case of Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome: A Unique Presentation and Management Challenges</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Muacevic</surname><given-names>Alexander</given-names></name></contrib><contrib contrib-type="editor"><name><surname>Adler</surname><given-names>John R</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Dayanand</surname><given-names>Lekhana</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>A.Y.</surname><given-names>Rahil</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>NK</surname><given-names>Rohan Krishna</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib></contrib-group><aff id="aff-1">
<label>1</label>
Internal Medicine, Fortis Hospital, Rajajinagar, Bengaluru, IND </aff><author-notes><corresp id="cor1">
Lekhana Dayanand <email>dlekhana@gmail.com</email>
</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>1</day><month>1</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><month>1</month><year>2025</year></pub-date><volume>17</volume><issue>1</issue><elocation-id>e76723</elocation-id><history><date date-type="accepted"><day>31</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025, Dayanand et al.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Dayanand et al.</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri xlink:href="https://www.cureus.com/articles/328527-adult-onset-stills-disease-with-normal-ferritin-levels-and-severe-sulfasalazine-induced-probable-case-of-drug-reaction-with-eosinophilia-and-systemic-symptoms-dress-syndrome-a-unique-presentation-and-management-challenges">This article is available from https://www.cureus.com/articles/328527-adult-onset-stills-disease-with-normal-ferritin-levels-and-severe-sulfasalazine-induced-probable-case-of-drug-reaction-with-eosinophilia-and-systemic-symptoms-dress-syndrome-a-unique-presentation-and-management-challenges</self-uri><abstract><p>Adult-onset Still's disease (AOSD) is an uncommon clinical condition with an uncertain cause, characterized by arthritis, fever, evanescent rash, and other systemic presentations. This case report describes a 26-year-old female who had a fever, arthralgia, vomiting, sore throat, bilateral distal extremities edema, hypertension, and normal ferritin. She was diagnosed with AOSD using the Yamaguchi criteria based on exclusion and was treated with hydroxychloroquine and sulfasalazine. The patient's arthralgia improved significantly. However, she returned with complaints of a diffuse erythematous burning, pruritic, maculopapular, non-evanescent rash caused by a severe reaction to sulfasalazine, with a skin biopsy revealing urticarial vasculitis, with probable DRESS (drug reaction with eosinophilia and systemic symptoms) syndrome. This was treated with topical and short-course oral steroids, intravenous antibiotics, and Janus kinase (JAK) inhibitor, improving her condition remarkably. To the best of our knowledge, there are no prior reports of a case of AOSD with normal ferritin levels that also exhibited a severe reaction to sulfasalazine, compounded by complications due to NSAIDs (nonsteroidal anti-inflammatory drugs) and steroid use. This rarity distinguishes our case report.</p></abstract><kwd-group kwd-group-type="author"><kwd>adult-onset still's disease</kwd><kwd>complications</kwd><kwd>dress syndrome</kwd><kwd>normal ferritin</kwd><kwd>nsaids</kwd><kwd>rash</kwd><kwd>steroids</kwd><kwd>sulfasalazine</kwd><kwd>urticarial vasculitis</kwd><kwd>yamaguchi criteria</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Adult-onset Still's disease (AOSD) was initially described in children by George F. Still in 1897. However, the disease was predominantly overlooked until Bywaters described it in 1971. AOSD is a rare systemic auto-inflammatory disorder with an unknown cause. It is distinguished by a clinical triad of persistent fever, polyarthritis, and rash [<xref rid="REF1" ref-type="bibr">1</xref>].</p><p>The condition has a bimodal age distribution of 15-25 and 36-46 years of age but mainly affects young individuals [<xref rid="REF2" ref-type="bibr">2</xref>]. The uncertainty in the presentation and the lack of serologic markers make AOSD diagnosis challenging and is, hence, a diagnosis of exclusion. Given the limitations, the Yamaguchi and Fautrel criteria remain the most commonly used diagnostic tools in clinical practice [<xref rid="REF3" ref-type="bibr">3</xref>].</p><p>Nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids (CS), and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) are mainly used for treatment. In certain instances, biological therapy, such as interleukin inhibitors, tumor necrosis factor-alpha, or Janus kinase (JAK) inhibitors, is administered in refractive cases [<xref rid="REF4" ref-type="bibr">4</xref>].</p><p>Herein, we aim to describe a case of AOSD presenting with normal ferritin levels and a severe drug reaction to sulfasalazine with complications&#x000a0;from the use of NSAIDs and steroids, which are the primary treatment modalities for this condition.</p></sec><sec sec-type="cases"><title>Case presentation</title><p>A 26-year-old female patient presented with a history of polyarthralgia for one month involving the small and the large joints symmetrically, associated with multiple episodes of non-bilious and non-blood-stained vomiting, sore throat, and fever, present for over three weeks, with no prior history or family history of similar episodes.&#x000a0;The fever episodes are&#x000a0;low-grade, intermittent, not associated with chills or rigors, and relieved after taking antipyretics. However, it is associated with an evanescent, non-pruritic macular rash, mainly over the patient's distal hands (Figure <xref rid="FIG1" ref-type="fig">1</xref>).</p><fig position="anchor" fig-type="figure" id="FIG1"><label>Figure 1</label><caption><title>An evanescent, non-pruritic macular rash over the patient's right distal hand, visible during febrile episodes only (arrow).</title></caption><graphic xlink:href="cureus-0017-00000076723-i01" position="float"/></fig><p>The patient was treated for possible viral arthritis at another outside hospital with analgesics including aceclofenac 100 mg + paracetamol 325 mg, twice daily, for two weeks, and etoricoxib 90 mg, once a day, for one week, with no significant improvement. Prednisolone, 40 mg once daily, was then added. She gradually developed bilateral distal extremity edema and vomiting over the next few days, which prompted her for a consultation.</p><p>The examination indicated an obese female with bilateral distal extremity pitting edema, blood pressure measuring 140/90 mmHg, and no fever at presentation, as she had taken an antipyretic pill before her consultation. Her throat was mildly congested, and occipital and a few cervical lymph nodes were palpable; mild hepatomegaly was appreciated. The musculoskeletal examination was significant for tenderness at the joints of bilateral wrists, bilateral interphalangeal joints of the hands and feet, bilateral knees, and bilateral shoulders. The skin examination showed a few non-pruritic macular rashes, mainly over the patient's distal&#x000a0;hands. However, other systemic examinations&#x000a0;were unremarkable. During her hospital stay, the patient had multiple episodes of fever in a day, with a recorded highest temperature of 104&#x000b0;F.</p><p>Hematological investigations were significant for leukocytosis, mild anemia, elevated&#x000a0;C-reactive protein (CRP), high erythrocyte sedimentation rate (ESR), and elevated serum creatinine. A peripheral smear suggested microcytic hypochromic anemia with leukocytosis. Her urine routine detected ketones, likely starvation ketosis, as her glycated hemoglobin was normal. Normal ferritin, coagulation profile, serum cortisol, serum electrolytes, and liver enzymes were noted, as seen in Table <xref rid="TAB1" ref-type="table">1</xref>. The chest X-ray was normal. An ultrasound of the abdomen and pelvis suggested mild hepatomegaly with minimal ascites.</p><table-wrap position="float" id="TAB1"><label>Table 1</label><caption><title>Comprehensive blood test report</title></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Parameter</td><td rowspan="1" colspan="1">Values</td><td rowspan="1" colspan="1">Range</td></tr><tr><td rowspan="1" colspan="1">White Blood Cell Count</td><td rowspan="1" colspan="1">12.80 thou/&#x000b5;L</td><td rowspan="1" colspan="1">4.0-10.0 thou/&#x000b5;L</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Red Blood Cell Count</td><td rowspan="1" colspan="1">4.08 mil/&#x000b5;L</td><td rowspan="1" colspan="1">3.8-4.8 mil/&#x000b5;L</td></tr><tr><td rowspan="1" colspan="1">Hemoglobin</td><td rowspan="1" colspan="1">10.8 g/dL</td><td rowspan="1" colspan="1">12.0-15.0 g/dL</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Neutrophils</td><td rowspan="1" colspan="1">85%</td><td rowspan="1" colspan="1">40-80%</td></tr><tr><td rowspan="1" colspan="1">Lymphocytes</td><td rowspan="1" colspan="1">23%</td><td rowspan="1" colspan="1">20-40%</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Eosinophils</td><td rowspan="1" colspan="1">02%</td><td rowspan="1" colspan="1">1-6 %</td></tr><tr><td rowspan="1" colspan="1">Platelet Count</td><td rowspan="1" colspan="1">288 thou/&#x000b5;L</td><td rowspan="1" colspan="1">150-410 thou/&#x000b5;L</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Serum Creatinine</td><td rowspan="1" colspan="1">1.32 mg/dL</td><td rowspan="1" colspan="1">0.60-1.10 mg/dL</td></tr><tr><td rowspan="1" colspan="1">Serum Urea</td><td rowspan="1" colspan="1">39 mg/dL</td><td rowspan="1" colspan="1">21-43 mg/dL</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Prothrombin Time</td><td rowspan="1" colspan="1">13.0 seconds</td><td rowspan="1" colspan="1">12.70-14.60 seconds</td></tr><tr><td rowspan="1" colspan="1">INR (International Normalized Ratio)</td><td rowspan="1" colspan="1">1.02 ratio</td><td rowspan="1" colspan="1">0.00-1.40 ratio</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">CRP (C-reactive Protein)</td><td rowspan="1" colspan="1">26.3 mg/L</td><td rowspan="1" colspan="1">3-10 mg/L</td></tr><tr><td rowspan="1" colspan="1">TSH (Thyroid-Stimulating Hormone)</td><td rowspan="1" colspan="1">1.20 &#x000b5;IU/mL</td><td rowspan="1" colspan="1">0.270-4.200 &#x000b5;IU/mL</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Hba1c (Glycated Hemoglobin)</td><td rowspan="1" colspan="1">5.8%</td><td rowspan="1" colspan="1">&#x0003c;6.2%: Normal; 6.3-7.0%: Good control; 7.1-8.0%: Fair control; &#x0003e;8.0%: Poor control</td></tr><tr><td rowspan="1" colspan="1">Serum Iron</td><td rowspan="1" colspan="1">13 &#x000b5;mol/L</td><td rowspan="1" colspan="1">14-32 &#x000b5;mol/L</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Serum Transferrin</td><td rowspan="1" colspan="1">295 mg/dL</td><td rowspan="1" colspan="1">204-360 mg/dL</td></tr><tr><td rowspan="1" colspan="1">Serum Ferritin</td><td rowspan="1" colspan="1">14.10 mcg/L</td><td rowspan="1" colspan="1">11-307 mcg/L</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Total Iron Binding Capacity</td><td rowspan="1" colspan="1">365 mcg/dL</td><td rowspan="1" colspan="1">240-450 mcg/dL</td></tr><tr><td rowspan="1" colspan="1">Serum Cortisol 8 a.m.</td><td rowspan="1" colspan="1">18 mcg/dL</td><td rowspan="1" colspan="1">5-23 mcg/dL</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Serum Cortisol 4 p.m.</td><td rowspan="1" colspan="1">7 mcg/dL</td><td rowspan="1" colspan="1">3-13 mcg/dL</td></tr><tr><td rowspan="1" colspan="1">Erythrocyte Sedimentation Rate (ESR)</td><td rowspan="1" colspan="1">18 mm/hour</td><td rowspan="1" colspan="1">0-15 mm/hour</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Direct Bilirubin</td><td rowspan="1" colspan="1">0.27 mg/dL</td><td rowspan="1" colspan="1">0.00-0.40 mg/dL</td></tr><tr><td rowspan="1" colspan="1">Total Bilirubin</td><td rowspan="1" colspan="1">0.46 mg/dL</td><td rowspan="1" colspan="1">0.3-1.2 mg/dL</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Aspartate Amino Transferase (AST/SGOT)</td><td rowspan="1" colspan="1">18 U/L</td><td rowspan="1" colspan="1">0.0-31.0 U/L</td></tr><tr><td rowspan="1" colspan="1">Alanine Aminotransferase (ALT/SGPT)</td><td rowspan="1" colspan="1">10 U/L</td><td rowspan="1" colspan="1">0.0-34.0 U/L</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Alkaline Phosphatase</td><td rowspan="1" colspan="1">47 U/L</td><td rowspan="1" colspan="1">42-98 U/L</td></tr><tr><td rowspan="1" colspan="1">Gamma-Glutamyl Transferase</td><td rowspan="1" colspan="1">7 U/L</td><td rowspan="1" colspan="1">0.0-38.0 U/L</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Serum Sodium</td><td rowspan="1" colspan="1">136 mmol/L</td><td rowspan="1" colspan="1">135-145 mmol/L</td></tr><tr><td rowspan="1" colspan="1">Serum Potassium</td><td rowspan="1" colspan="1">4 mmol/L</td><td rowspan="1" colspan="1">3.6-5.0 mmol/L</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Serum Chloride</td><td rowspan="1" colspan="1">105 mmol/L</td><td rowspan="1" colspan="1">98-107 mmol/L</td></tr></tbody></table></table-wrap><p>The infectious workup&#x000a0;was unremarkable, including a throat swab, urine culture, blood culture, and tests (Table <xref rid="TAB2" ref-type="table">2</xref>).</p><table-wrap position="float" id="TAB2"><label>Table 2</label><caption><title>Infectious workup profile</title><p>HIV: human immunodeficiency virus</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Parameter Name</td><td rowspan="1" colspan="1">Result</td><td rowspan="1" colspan="1">Method</td></tr><tr><td rowspan="1" colspan="1">HIV-1 Antibodies</td><td rowspan="1" colspan="1">Non-reactive</td><td rowspan="1" colspan="1">Rapid Card Test</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">HIV-2 Antibodies</td><td rowspan="1" colspan="1">Non-reactive</td><td rowspan="1" colspan="1">Rapid Card Test</td></tr><tr><td rowspan="1" colspan="1">Hepatitis B Surface Antigen</td><td rowspan="1" colspan="1">Non-reactive</td><td rowspan="1" colspan="1">Rapid Card Test</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Hepatitis C Antibodies</td><td rowspan="1" colspan="1">Non-reactive</td><td rowspan="1" colspan="1">Rapid Card Test</td></tr><tr><td rowspan="1" colspan="1">Chikungunya</td><td rowspan="1" colspan="1">Non-reactive</td><td rowspan="1" colspan="1">Rapid Card Test</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Dengue</td><td rowspan="1" colspan="1">Non-reactive</td><td rowspan="1" colspan="1">ELISA</td></tr><tr><td rowspan="1" colspan="1">Weil-Felix</td><td rowspan="1" colspan="1">Non-reactive</td><td rowspan="1" colspan="1">Agglutination Test</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Leptospira</td><td rowspan="1" colspan="1">Non-reactive</td><td rowspan="1" colspan="1">Microagglutination Test</td></tr><tr><td rowspan="1" colspan="1">Scrub Typhus</td><td rowspan="1" colspan="1">Non-reactive</td><td rowspan="1" colspan="1">ELISA</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Mycoplasma pneumoniae</td><td rowspan="1" colspan="1">Non-reactive</td><td rowspan="1" colspan="1">ELISA</td></tr><tr><td rowspan="1" colspan="1">Antistreptolysin O</td><td rowspan="1" colspan="1">Non-reactive</td><td rowspan="1" colspan="1">ELISA</td></tr></tbody></table></table-wrap><p>The workup for autoimmune and inflammatory etiology was unremarkable (Table <xref rid="TAB3" ref-type="table">3</xref>).</p><table-wrap position="float" id="TAB3"><label>Table 3</label><caption><title>Autoimmune profile</title></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Antinuclear Antibody (ANA) Profile Serum</td><td rowspan="1" colspan="1">Result</td><td rowspan="1" colspan="1">Method</td></tr><tr><td rowspan="1" colspan="1">nRNP/Sm (Nuclear Ribonucleoprotein)</td><td rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">ELISA</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Sm (Smith)</td><td rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">ELISA</td></tr><tr><td rowspan="1" colspan="1">SS-A (Sjogren's Syndrome A)</td><td rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">ELISA</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Ro-52 (TRIM21)</td><td rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">ELISA</td></tr><tr><td rowspan="1" colspan="1">SS-B/La (Sjogren's Syndrome B)</td><td rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">ELISA</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Scl-70 ( DNA Topoisomerase I)</td><td rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">ELISA</td></tr><tr><td rowspan="1" colspan="1">PM-Scl (Polymyositis/Scleroderma)</td><td rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">ELISA</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Jo-1 (Histidyl-tRNA Synthetase)</td><td rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">ELISA</td></tr><tr><td rowspan="1" colspan="1">CENP-B (Centromere B)</td><td rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">ELISA</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">PCNA (Proliferating Cell Nuclear Antigen)</td><td rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">ELISA</td></tr><tr><td rowspan="1" colspan="1">ds (double-stranded) DNA</td><td rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">ELISA</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Nucleosomes</td><td rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">ELISA</td></tr><tr><td rowspan="1" colspan="1">Histones</td><td rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">ELISA</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Rib-P (Ribosomal P) Protein</td><td rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">ELISA</td></tr><tr><td rowspan="1" colspan="1">AMA-M2 (Antimitochondrial M2)</td><td rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">ELISA</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Rheumatoid Factor</td><td rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">ELISA</td></tr><tr><td rowspan="1" colspan="1">Anti-CCP (Cyclic Citrullinated Peptide)</td><td rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">ELISA</td></tr></tbody></table></table-wrap><p>Given her clinical features and review of the laboratory values, in the absence of other identifiable causes,&#x000a0;she was diagnosed with AOSD using the Yamaguchi criteria. As the patient had no past or family history of&#x000a0;drug allergies, she was discharged on hydroxychloroquine 200 mg twice daily, sulfasalazine 500 mg twice daily, and suitable anti-hypertensives.</p><p>Over the next few days, the patient became afebrile, and the arthralgia improved significantly. The patient subsequently presented one week post-discharge with diffuse erythematous maculopapular, burning, non-evanescent, and itchy rash involving&#x000a0;her entire body (Figures <xref rid="FIG2" ref-type="fig">2</xref>,&#x000a0;<xref rid="FIG3" ref-type="fig">3</xref>). The rash was associated with fever (103&#x000b0;F), peripheral smear suggesting microcytic hypochromic anemia with leukocytosis and a few atypical lymphocytes, facial edema, distal extremities edema, and cervical&#x000a0;and occipital lymphadenopathy.</p><fig position="anchor" fig-type="figure" id="FIG2"><label>Figure 2</label><caption><title>Diffuse erythematous maculopapular, burning, non-evanescent, and itchy rash on the patient's right hand.</title></caption><graphic xlink:href="cureus-0017-00000076723-i02" position="float"/></fig><fig position="anchor" fig-type="figure" id="FIG3"><label>Figure 3</label><caption><title>Diffuse erythematous maculopapular, burning, non-evanescent, and itchy rash on the patient's left hand.</title></caption><graphic xlink:href="cureus-0017-00000076723-i03" position="float"/></fig><p>It was suspected to be a drug reaction to sulfasalazine, and&#x000a0;immediately, the drug was stopped. Owing to the additional symptoms associated with the rash, a diagnosis of probable DRESS (drug reaction with eosinophilia and systemic symptoms) syndrome was made. The rash was treated with antihistamines to provide the patient with symptomatic relief from itching. A dermatology opinion was sought, and a skin biopsy was ordered, which revealed urticarial vasculitis (UV) (Figure <xref rid="FIG4" ref-type="fig">4</xref>).</p><fig position="anchor" fig-type="figure" id="FIG4"><label>Figure 4</label><caption><title>Microscopic examination of the skin biopsy showing fused rete ridges and mild spongiosis, with the superficial dermis having perivascular lymphocytic infiltrates (green arrow), along with rare neutrophils. The surrounding stroma has extravasated red blood cells (orange arrow) and a few karyorrhectic debris. The deeper dermis is within normal limits and shows normal-appearing adnexal structures. No neutrophilic collections. No epidermal necrosis or atypia. Consistent with urticarial vasculitis.</title></caption><graphic xlink:href="cureus-0017-00000076723-i04" position="float"/></fig><p>The patient was then treated with topical steroids, low-dose oral steroids, a short course of intravenous&#x000a0;antibiotics (to prevent secondary bacterial skin infection), and a JAK inhibitor, tofacitinib, which provided significant improvement. The rashes started resolving with peeling and&#x000a0;collarette of scales (Figures&#x000a0;<xref rid="FIG5" ref-type="fig">5</xref>, <xref rid="FIG6" ref-type="fig">6</xref>). The steroids were successfully tapered off over the next few weeks, and her&#x000a0;symptoms were completely resolved. At present, she is on hydroxychloroquine 200 mg.</p><fig position="anchor" fig-type="figure" id="FIG5"><label>Figure 5</label><caption><title>Rashes resolving with peeling and collarette of scales. Plantar and medial aspects of the foot.</title></caption><graphic xlink:href="cureus-0017-00000076723-i05" position="float"/></fig><fig position="anchor" fig-type="figure" id="FIG6"><label>Figure 6</label><caption><title>Rashes resolving with peeling and collarette of scales. Dorsal aspect of the foot.</title></caption><graphic xlink:href="cureus-0017-00000076723-i06" position="float"/></fig></sec><sec sec-type="discussion"><title>Discussion</title><p>Still's disease is a systemic inflammatory response disorder with an unclear etiopathogenesis. Its symptoms include fever, rash, sore throat, and arthralgia. However, patients may also present with other clinical features, such as sore throat, lymphadenopathy, serositis, hepatomegaly, and splenomegaly [<xref rid="REF1" ref-type="bibr">1</xref>].</p><p>Although AOSD is a diagnosis of exclusion, clinicians can use the Yamaguchi [<xref rid="REF5" ref-type="bibr">5</xref>] or Fautrel [<xref rid="REF6" ref-type="bibr">6</xref>] criteria to aid in the diagnosis. The former criteria require that five or more criteria be met, with at least two major criteria, and infection, malignancies, and other rheumatic diseases ruled out. It has&#x000a0;a sensitivity of 96.2% and a specificity of 92.1%&#x000a0;[<xref rid="REF5" ref-type="bibr">5</xref>]. The latter criteria require at least four or more major or three major and two minor criteria to be met. It has a sensitivity of 80.6% and a specificity of 98.5% [<xref rid="REF6" ref-type="bibr">6</xref>].</p><p>Our patient's clinical characteristics met the Yamaguchi criteria, with ferritin levels within the normal range, as detailed in Table <xref rid="TAB4" ref-type="table">4</xref>. Conventionally, elevated serum ferritin levels are considered&#x000a0;a powerful diagnostic marker for AOSD [<xref rid="REF7" ref-type="bibr">7</xref>]. However, multiple well-documented cases of AOSD have been reported in which ferritin levels remain unaltered, suggesting the existence of alternative underlying mechanisms [<xref rid="REF8" ref-type="bibr">8</xref>], thereby rendering it non-pathognomonic for AOSD diagnosis [<xref rid="REF9" ref-type="bibr">9</xref>].</p><table-wrap position="float" id="TAB4"><label>Table 4</label><caption><title>Yamaguchi criteria for adult-onset Still's disease (AOSD). Our case is positive for the diagnosis of AOSD</title><p>For a positive diagnosis, five or more criteria must be met, with at least two major criteria, and infection, malignancies, and other rheumatic diseases must be ruled out [<xref rid="REF5" ref-type="bibr">5</xref>].</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Yamaguchi Criteria</td><td rowspan="1" colspan="1">Result</td></tr><tr><td colspan="2" rowspan="1">Major criteria</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">&#x000a0; &#x000a0; Fever &#x02265;39&#x000b0;C lasting &#x02265;1 week</td><td rowspan="1" colspan="1">Present</td></tr><tr><td rowspan="1" colspan="1">&#x000a0; &#x000a0; Arthralgia or arthritis lasting &#x02265;2 weeks</td><td rowspan="1" colspan="1">Present</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">&#x000a0; &#x000a0; A nonpruritic macular or maculopapular skin rash that is salmon-colored and usually found over the trunk or extremities during febrile episodes</td><td rowspan="1" colspan="1">Present</td></tr><tr><td rowspan="1" colspan="1">&#x000a0; &#x000a0; Leukocytosis (&#x02265;10,000/mL), with &#x02265;80 % granulocytes</td><td rowspan="1" colspan="1">Present</td></tr><tr style="background-color:#ccc"><td colspan="2" rowspan="1">Minor criteria</td></tr><tr><td rowspan="1" colspan="1">&#x000a0; &#x000a0; Sore throat</td><td rowspan="1" colspan="1">Present</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">&#x000a0; &#x000a0; Lymphadenopathy</td><td rowspan="1" colspan="1">Present</td></tr><tr><td rowspan="1" colspan="1">&#x000a0; &#x000a0; Hepatomegaly or splenomegaly</td><td rowspan="1" colspan="1">Present</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">&#x000a0; &#x000a0; Abnormal liver function studies, particularly elevations in aspartate and alanine aminotransferase and lactate dehydrogenase levels</td><td rowspan="1" colspan="1">Not present</td></tr><tr><td rowspan="1" colspan="1">&#x000a0; &#x000a0; Negative tests for antinuclear antibody and rheumatoid factor</td><td rowspan="1" colspan="1">Present</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Exclusion criteria: infections, malignancies, and other rheumatic diseases</td><td rowspan="1" colspan="1">Excluded</td></tr></tbody></table></table-wrap><p>Ferritin is one of the&#x000a0;acute phase reactants, with levels often elevated during inflammation [<xref rid="REF10" ref-type="bibr">10</xref>]. Additionally, it is well established that steroid therapy attenuates the acute-phase reactant response [<xref rid="REF11" ref-type="bibr">11</xref>]. In the case at hand, the patient had initially received steroid therapy for her polyarthralgia, which may explain the normal ferritin levels observed during admission. Conversely, it could also represent AOSD with normal ferritin levels.</p><p>The patient's polyarthralgia was initially treated with&#x000a0;corticosteroids and NSAIDs, both of which are known to cause increased blood pressure and fluid retention, as seen in this case [<xref rid="REF12" ref-type="bibr">12</xref>,<xref rid="REF13" ref-type="bibr">13</xref>]. NSAIDs cause this&#x000a0;by inhibiting the cyclo-oxygenase enzyme,&#x000a0;thereby resulting&#x000a0;in acute kidney injury&#x000a0;[<xref rid="REF13" ref-type="bibr">13</xref>], as evidenced by elevated serum creatinine levels in our case. The levels&#x000a0;subsequently normalized once the NSAIDs were stopped and treatment was initiated.</p><p>Our case also presented with diffuse, erythematous, maculopapular, burning, and pruritic rash involving her entire body one week after discharge with sulfasalazine. Recent trends indicate a rise in atypical cutaneous manifestations, observed in approximately 14% of AOSD cases, with various skin manifestations [<xref rid="REF14" ref-type="bibr">14</xref>]. In our case, the cutaneous presentation is due to a drug reaction to sulfasalazine with biopsy-proven UV.&#x000a0;Sulfasalazine&#x000a0;is known to have cutaneous side effects ranging from benign, self-limiting rashes to more severe manifestations such as leukocytoclastic vasculitis [<xref rid="REF15" ref-type="bibr">15</xref>], which is a feature seen in UV [<xref rid="REF16" ref-type="bibr">16</xref>]. UV&#x000a0;can also be one of the extrapulmonary manifestations of <italic>Mycoplasma pneumoniae</italic>, which can be associated with other symptoms mimicking AOSD [<xref rid="REF17" ref-type="bibr">17</xref>]. However, our case was negative for its serology. Drug-induced vasculitis was hence strongly suspected as the cause only after other causes of UV were ruled out.</p><p>Such side effects of sulfasalazine are more frequently observed in patients with AOSD, ranging from mild symptoms such as nausea, vomiting, abdominal pain, facial flushing, and rashes&#x000a0;to more severe reactions, including hypotension, myelosuppression, and even death [<xref rid="REF18" ref-type="bibr">18</xref>]. Sulfasalazine remains a viable treatment option unless contraindications or significant adverse events arise. Given that some adverse effects have been reported in AOSD patients [<xref rid="REF18" ref-type="bibr">18</xref>], this should not entirely preclude its use&#x000a0;in the treatment, provided careful monitoring is in place.</p><p>The cutaneous presentation after sulfasalazine use, along with other features such as fever, enlarged lymph nodes, and blood count abnormality in our case, shines light on DRESS&#x000a0;syndrome [<xref rid="REF19" ref-type="bibr">19</xref>]. Hence, the European Registry for Severe Cutaneous Adverse Reactions (RegiSCAR) criteria were applied, a&#x000a0;scoring system for classifying DRESS cases as definite, probable, possible, or no case [<xref rid="REF20" ref-type="bibr">20</xref>]. Our case belongs to a probable case of DRESS syndrome (Table <xref rid="TAB5" ref-type="table">5</xref>).</p><table-wrap position="float" id="TAB5"><label>Table 5</label><caption><title>The European RegiSCAR scoring system [<xref rid="REF20" ref-type="bibr">20</xref>] for diagnosing DRESS syndrome</title><p>A diagnosis of DRESS syndrome is categorized as follows: definite (score &#x0003e; 5), probable (score 4&#x02013;5), possible (score 2&#x02013;3), or ruled out (score &#x0003c; 2), according to the score obtained.&#x000a0;Our case records a score of 4, categorizing it as a probable case of DRESS syndrome.</p><p>* Maculopapular rash and two of the following: (1) facial edema; (2) psoriasiform desquamation; (3) infiltrated skin lesions; (4) purpuric lesions involving areas other than legs. Our case had facial edema and&#x000a0;psoriasiform desquamation with maculopapular rash.</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="2" colspan="1">Criteria</td><td colspan="4" rowspan="1">Score</td><td rowspan="2" colspan="1">Result of Our Case</td></tr><tr><td rowspan="1" colspan="1">-1</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">+1</td><td rowspan="1" colspan="1">+2</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Fever&#x02009;&#x02265;&#x02009;38.5&#x000b0;C (core) or&#x02009;&#x02265;&#x02009;38&#x000b0;C (axillary)</td><td rowspan="1" colspan="1">No/Unknown</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">Yes (Score: 0)</td></tr><tr><td rowspan="1" colspan="1">Enlarged lymph nodes (&#x02265;2 sites, &#x0003e;1&#x02009;cm)</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">No/Unknown</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">Yes (Score:+1)</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Eosinophils</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">No/Unknown</td><td rowspan="1" colspan="1">700-1490</td><td rowspan="1" colspan="1">&#x02265;1,500</td><td rowspan="1" colspan="1">No (Score: 0)</td></tr><tr><td rowspan="1" colspan="1">Eosinophils, if leukocytes &#x0003c;4&#x02009;&#x000d7;&#x02009;10<sup>9</sup>/L</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">No/Unknown</td><td rowspan="1" colspan="1">10.0&#x02013;19.9%</td><td rowspan="1" colspan="1">&#x02265;20%</td><td rowspan="1" colspan="1">No (Score: 0)</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Atypical lymphocytes</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">No/Unknown</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">Yes (Score:+1)</td></tr><tr><td rowspan="1" colspan="1">Skin rash extent (&#x0003e;50% body surface area)</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">No/Unknown</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">Yes (Score:+1)</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Skin rash suggesting DRESS*</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">Unknown</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">Yes (Score:+1)</td></tr><tr><td rowspan="1" colspan="1">Biopsy suggesting DRESS</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">Yes/Unknown</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">No (Score: -1)</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">One organ involvement</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">No/Unknown</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">No (Score: 0)</td></tr><tr><td rowspan="1" colspan="1">Two or more organ involvement</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">No/Unknown</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">No (Score: 0)</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Resolution in &#x02265;15&#x02009;days</td><td rowspan="1" colspan="1">No/Unknown</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">Yes (Score: 0)</td></tr><tr><td rowspan="1" colspan="1">At least 3 biological negative investigations done&#x000a0;to exclude other causes</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">No/Unknown</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">Yes (Score:+1)</td></tr></tbody></table></table-wrap><p>Our case emphasizes the fact that AOSD should always be considered a possibility in a patient presenting with arthralgia, pyrexia of unknown origin, and a rash, irrespective of the ferritin value. A diagnosis of AOSD can be made even with normal ferritin levels. To the best of our knowledge, a case of AOSD with normal ferritin levels, developing a severe reaction to the use of sulfasalazine, and complications secondary to the use of NSAIDs and steroids have never been reported, which distinguishes this case.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>This case highlights the variability and complexity of the clinical presentation of AOSD. It underscores the need for clinicians to consider AOSD as a differential diagnosis in patients presenting with fever, arthralgia, and rash, even when ferritin levels are not elevated. Furthermore, the case emphasizes the potential adverse reactions to treatment, particularly sulfasalazine, which led to biopsy-proven UV and a probable DRESS syndrome diagnosis. The clinical course was further complicated by the side effects of NSAIDs and steroid therapy. This case, with its unique constellation of symptoms and reactions, serves as a valuable contribution to the existing body of knowledge on AOSD, emphasizing the need for personalized treatment approaches, considering the patient's idiosyncrasies,&#x000a0;and careful monitoring of patients when&#x000a0;on&#x000a0;therapeutic agents.</p></sec></body><back><fn-group content-type="conflict"><title>Disclosures</title><fn fn-type="COI-statement"><p><bold>Human subjects:</bold> Consent for treatment and open access publication was obtained or waived by all participants in this study.</p><p><bold>Conflicts of interest:</bold> In compliance with the ICMJE uniform disclosure form, all authors declare the following:</p><p><bold>Payment/services info:</bold> All authors have declared that no financial support was received from any organization for the submitted work.</p><p><bold>Financial relationships:</bold> All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.</p><p><bold>Other relationships:</bold> All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</p></fn></fn-group><fn-group content-type="other"><title>Author Contributions</title><fn fn-type="other"><p><bold>Concept and design:</bold>&#x000a0; Lekhana Dayanand, Rahil A.Y., Rohan Krishna NK</p><p><bold>Acquisition, analysis, or interpretation of data:</bold>&#x000a0; Lekhana Dayanand, Rahil A.Y., Rohan Krishna NK</p><p><bold>Drafting of the manuscript:</bold>&#x000a0; Lekhana Dayanand, Rahil A.Y., Rohan Krishna NK</p><p><bold>Critical review of the manuscript for important intellectual content:</bold>&#x000a0; Lekhana Dayanand, Rahil A.Y., Rohan Krishna NK</p></fn></fn-group><ref-list><title>References</title><ref id="REF1"><label>1</label><element-citation publication-type="journal"><article-title>Still's disease in the adult</article-title><source>Ann Rheum Dis</source><person-group>
<name><surname>Bywaters</surname><given-names>EG</given-names></name>
</person-group><fpage>121</fpage><lpage>133</lpage><volume>30</volume><year>1971</year><uri xlink:href="https://pmc.ncbi.nlm.nih.gov/articles/PMC1005739/">https://pmc.ncbi.nlm.nih.gov/articles/PMC1005739/</uri><pub-id pub-id-type="pmid">5315135</pub-id>
</element-citation></ref><ref id="REF2"><label>2</label><element-citation publication-type="journal"><article-title>Adult-onset Still's disease in a patient over 80 years old successfully treated with low-dose methotrexate therapy</article-title><source>Age Ageing</source><person-group>
<name><surname>Kurasawa</surname><given-names>M</given-names></name>
<name><surname>Kotani</surname><given-names>K</given-names></name>
<name><surname>Kurasawa</surname><given-names>G</given-names></name>
<name><surname>Shida</surname><given-names>K</given-names></name>
<name><surname>Yamada</surname><given-names>S</given-names></name>
<name><surname>Tago</surname><given-names>T</given-names></name>
</person-group><fpage>104</fpage><lpage>106</lpage><volume>36</volume><year>2007</year><uri xlink:href="https://pubmed.ncbi.nlm.nih.gov/17158115/">https://pubmed.ncbi.nlm.nih.gov/17158115/</uri><pub-id pub-id-type="pmid">17158115</pub-id>
</element-citation></ref><ref id="REF3"><label>3</label><element-citation publication-type="journal"><article-title>Adult-onset Still's disease in focus: clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies</article-title><source>Semin Arthritis Rheum</source><person-group>
<name><surname>Efthimiou</surname><given-names>P</given-names></name>
<name><surname>Kontzias</surname><given-names>A</given-names></name>
<name><surname>Hur</surname><given-names>P</given-names></name>
<name><surname>Rodha</surname><given-names>K</given-names></name>
<name><surname>Ramakrishna</surname><given-names>GS</given-names></name>
<name><surname>Nakasato</surname><given-names>P</given-names></name>
</person-group><fpage>858</fpage><lpage>874</lpage><volume>51</volume><year>2021</year><uri xlink:href="https://www.sciencedirect.com/science/article/pii/S0049017221001177?via%3Dihub">https://www.sciencedirect.com/science/article/pii/S0049017221001177?via%3Dihub</uri><pub-id pub-id-type="pmid">34175791</pub-id>
</element-citation></ref><ref id="REF4"><label>4</label><element-citation publication-type="journal"><article-title>Adult-onset Still&#x02019;s disease&#x02014;a complex disease, a challenging treatment</article-title><source>Int J Mol Sci</source><person-group>
<name><surname>Macovei</surname><given-names>LA</given-names></name>
<name><surname>Burlui</surname><given-names>A</given-names></name>
<name><surname>Bratoiu</surname><given-names>I</given-names></name>
<etal/>
</person-group><fpage>12810</fpage><volume>23</volume><year>2022</year><uri xlink:href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9655522/">https://pmc.ncbi.nlm.nih.gov/articles/PMC9655522/</uri><pub-id pub-id-type="pmid">36361602</pub-id>
</element-citation></ref><ref id="REF5"><label>5</label><element-citation publication-type="journal"><article-title>Preliminary criteria for classification of adult Still's disease</article-title><source>J Rheumatol</source><person-group>
<name><surname>Yamaguchi</surname><given-names>M</given-names></name>
<name><surname>Ohta</surname><given-names>A</given-names></name>
<name><surname>Tsunematsu</surname><given-names>T</given-names></name>
<etal/>
</person-group><fpage>424</fpage><lpage>430</lpage><volume>19</volume><year>1992</year><uri xlink:href="https://pubmed.ncbi.nlm.nih.gov/1578458/">https://pubmed.ncbi.nlm.nih.gov/1578458/</uri><pub-id pub-id-type="pmid">1578458</pub-id>
</element-citation></ref><ref id="REF6"><label>6</label><element-citation publication-type="journal"><article-title>Proposal for a new set of classification criteria for adult-onset still disease</article-title><source>Medicine (Baltimore)</source><person-group>
<name><surname>Fautrel</surname><given-names>B</given-names></name>
<name><surname>Zing</surname><given-names>E</given-names></name>
<name><surname>Golmard</surname><given-names>JL</given-names></name>
<etal/>
</person-group><fpage>194</fpage><lpage>200</lpage><volume>81</volume><year>2002</year><uri xlink:href="https://journals.lww.com/md-journal/fulltext/2002/05000/proposal_for_a_new_set_of_classification_criteria.3.aspx">https://journals.lww.com/md-journal/fulltext/2002/05000/proposal_for_a_new_set_of_classification_criteria.3.aspx</uri><pub-id pub-id-type="pmid">11997716</pub-id>
</element-citation></ref><ref id="REF7"><label>7</label><element-citation publication-type="journal"><article-title>Diagnostic value of ferritin and glycosylated ferritin in adult onset Still's disease</article-title><source>J Rheumatol</source><person-group>
<name><surname>Fautrel</surname><given-names>B</given-names></name>
<name><surname>Le Mo&#x000eb;l</surname><given-names>G</given-names></name>
<name><surname>Saint-Marcoux</surname><given-names>B</given-names></name>
<etal/>
</person-group><fpage>322</fpage><lpage>329</lpage><volume>28</volume><year>2001</year><uri xlink:href="https://www.jrheum.org/content/jrheum/28/2/322.full.pdf">https://www.jrheum.org/content/jrheum/28/2/322.full.pdf</uri><pub-id pub-id-type="pmid">11246670</pub-id>
</element-citation></ref><ref id="REF8"><label>8</label><element-citation publication-type="journal"><article-title>Ferritin in adult-onset still's disease: just a useful innocent bystander?</article-title><source>Int J Inflam</source><person-group>
<name><surname>Mehta</surname><given-names>B</given-names></name>
<name><surname>Efthimiou</surname><given-names>P</given-names></name>
</person-group><fpage>298405</fpage><volume>2012</volume><year>2012</year><uri xlink:href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3321299/">https://pmc.ncbi.nlm.nih.gov/articles/PMC3321299/</uri><pub-id pub-id-type="pmid">22536541</pub-id>
</element-citation></ref><ref id="REF9"><label>9</label><element-citation publication-type="journal"><article-title>Adult-onset Still disease</article-title><source>Best Pract Res Clin Rheumatol</source><person-group>
<name><surname>Fautrel</surname><given-names>B</given-names></name>
</person-group><fpage>773</fpage><lpage>792</lpage><volume>22</volume><year>2008</year><uri xlink:href="https://www.sciencedirect.com/science/article/abs/pii/S1521694208000922?via%3Dihub">https://www.sciencedirect.com/science/article/abs/pii/S1521694208000922?via%3Dihub</uri><pub-id pub-id-type="pmid">19028363</pub-id>
</element-citation></ref><ref id="REF10"><label>10</label><element-citation publication-type="book"><article-title>Physiology, acute phase reactants</article-title><source>StatPearls [Internet]</source><person-group>
<name><surname>Gulhar</surname><given-names>R</given-names></name>
<name><surname>Ashraf</surname><given-names>MA</given-names></name>
<name><surname>Jialal</surname><given-names>I</given-names></name>
</person-group><publisher-loc>Treasure Island (FL)</publisher-loc><publisher-name>StatPearls Publishing</publisher-name><year>2023</year><uri xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK519570/">https://www.ncbi.nlm.nih.gov/books/NBK519570/</uri></element-citation></ref><ref id="REF11"><label>11</label><element-citation publication-type="journal"><article-title>Steroid therapy attenuates acute phase reactant response among children on ventricular assist device support</article-title><source>Ann Thorac Surg</source><person-group>
<name><surname>Byrnes</surname><given-names>JW</given-names></name>
<name><surname>Bhutta</surname><given-names>AT</given-names></name>
<name><surname>Rettiganti</surname><given-names>MR</given-names></name>
<etal/>
</person-group><fpage>1392</fpage><lpage>1398</lpage><volume>99</volume><year>2015</year><uri xlink:href="https://www.annalsthoracicsurgery.org/article/S0003-4975(14)02213-9/fulltext">https://www.annalsthoracicsurgery.org/article/S0003-4975(14)02213-9/fulltext</uri><pub-id pub-id-type="pmid">25669667</pub-id>
</element-citation></ref><ref id="REF12"><label>12</label><element-citation publication-type="journal"><article-title>Systematic review of the toxicity of short-course oral corticosteroids in children</article-title><source>Arch Dis Child</source><person-group>
<name><surname>Aljebab</surname><given-names>F</given-names></name>
<name><surname>Choonara</surname><given-names>I</given-names></name>
<name><surname>Conroy</surname><given-names>S</given-names></name>
</person-group><fpage>365</fpage><lpage>370</lpage><volume>101</volume><year>2016</year><uri xlink:href="https://adc.bmj.com/content/101/4/365">https://adc.bmj.com/content/101/4/365</uri><pub-id pub-id-type="pmid">26768830</pub-id>
</element-citation></ref><ref id="REF13"><label>13</label><element-citation publication-type="journal"><article-title>Acute kidney injury associated with non-steroidal anti-inflammatory drugs</article-title><source>Eur J Intern Med</source><person-group>
<name><surname>Klomjit</surname><given-names>N</given-names></name>
<name><surname>Ungprasert</surname><given-names>P</given-names></name>
</person-group><fpage>21</fpage><lpage>28</lpage><volume>101</volume><year>2022</year><uri xlink:href="https://www.ejinme.com/article/S0953-6205(22)00172-8/abstract">https://www.ejinme.com/article/S0953-6205(22)00172-8/abstract</uri><pub-id pub-id-type="pmid">35534373</pub-id>
</element-citation></ref><ref id="REF14"><label>14</label><element-citation publication-type="journal"><article-title>Adult-onset Still's disease with atypical cutaneous manifestations</article-title><source>Medicine (Baltimore)</source><person-group>
<name><surname>Narv&#x000e1;ez Garcia</surname><given-names>FJ</given-names></name>
<name><surname>Pascual</surname><given-names>M</given-names></name>
<name><surname>L&#x000f3;pez de Recalde</surname><given-names>M</given-names></name>
<etal/>
</person-group><fpage>0</fpage><volume>96</volume><year>2017</year><uri xlink:href="https://journals.lww.com/md-journal/fulltext/2017/03170/adult_onset_still_s_disease_with_atypical.28.aspx">https://journals.lww.com/md-journal/fulltext/2017/03170/adult_onset_still_s_disease_with_atypical.28.aspx</uri></element-citation></ref><ref id="REF15"><label>15</label><element-citation publication-type="journal"><article-title>Sulfasalazine induced leukocytoclastic vasculitis resulting in gangrene</article-title><source>Rheumatology (Oxford)</source><person-group>
<name><surname>Alamlih</surname><given-names>L</given-names></name>
<name><surname>Al-Karaja</surname><given-names>L</given-names></name>
<name><surname>Amro</surname><given-names>D</given-names></name>
<name><surname>Alnatsheh</surname><given-names>M</given-names></name>
</person-group><fpage>0</fpage><lpage>8</lpage><volume>62</volume><year>2023</year><uri xlink:href="https://academic.oup.com/rheumatology/article/62/4/e117/6675450?login=false">https://academic.oup.com/rheumatology/article/62/4/e117/6675450?login=false</uri></element-citation></ref><ref id="REF16"><label>16</label><element-citation publication-type="journal"><article-title>Urticarial vasculitis</article-title><source>Int J Womens Dermatol</source><person-group>
<name><surname>Gu</surname><given-names>SL</given-names></name>
<name><surname>Jorizzo</surname><given-names>JL</given-names></name>
</person-group><fpage>290</fpage><lpage>297</lpage><volume>7</volume><year>2021</year><uri xlink:href="https://www.sciencedirect.com/science/article/pii/S2352647521000241?via%3Dihub">https://www.sciencedirect.com/science/article/pii/S2352647521000241?via%3Dihub</uri><pub-id pub-id-type="pmid">34222586</pub-id>
</element-citation></ref><ref id="REF17"><label>17</label><element-citation publication-type="journal"><article-title>Mycoplasma pneumoniae infection associated with urticarial vasculitis mimicking adult-onset Still's disease</article-title><source>Rheumatol Int</source><person-group>
<name><surname>Dua</surname><given-names>J</given-names></name>
<name><surname>Nandagudi</surname><given-names>A</given-names></name>
<name><surname>Sutcliffe</surname><given-names>N</given-names></name>
</person-group><fpage>4053</fpage><lpage>4056</lpage><volume>32</volume><year>2012</year><uri xlink:href="https://link.springer.com/article/10.1007/s00296-011-2107-4">https://link.springer.com/article/10.1007/s00296-011-2107-4</uri><pub-id pub-id-type="pmid">21918897</pub-id>
</element-citation></ref><ref id="REF18"><label>18</label><element-citation publication-type="journal"><article-title>High toxicity of sulfasalazine in adult-onset Still's disease</article-title><source>Clin Exp Rheumatol</source><person-group>
<name><surname>Jung</surname><given-names>JH</given-names></name>
<name><surname>Jun</surname><given-names>JB</given-names></name>
<name><surname>Yoo</surname><given-names>DH</given-names></name>
<etal/>
</person-group><fpage>245</fpage><lpage>248</lpage><volume>18</volume><year>2000</year><uri xlink:href="https://www.clinexprheumatol.org/article.asp?a=1587">https://www.clinexprheumatol.org/article.asp?a=1587</uri><pub-id pub-id-type="pmid">10812499</pub-id>
</element-citation></ref><ref id="REF19"><label>19</label><element-citation publication-type="journal"><article-title>Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome and the rheumatologist</article-title><source>Curr Rheumatol Rep</source><person-group>
<name><surname>Adwan</surname><given-names>MH</given-names></name>
</person-group><fpage>3</fpage><volume>19</volume><year>2017</year><uri xlink:href="https://link.springer.com/article/10.1007/s11926-017-0626-z">https://link.springer.com/article/10.1007/s11926-017-0626-z</uri><pub-id pub-id-type="pmid">28138822</pub-id>
</element-citation></ref><ref id="REF20"><label>20</label><element-citation publication-type="journal"><article-title>Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome in childhood: a narrative review</article-title><source>Front Med (Lausanne)</source><person-group>
<name><surname>Manieri</surname><given-names>E</given-names></name>
<name><surname>Dondi</surname><given-names>A</given-names></name>
<name><surname>Neri</surname><given-names>I</given-names></name>
<name><surname>Lanari</surname><given-names>M</given-names></name>
</person-group><fpage>1108345</fpage><volume>10</volume><year>2023</year><pub-id pub-id-type="pmid">37575981</pub-id>
</element-citation></ref></ref-list></back></article>